Investment Rating - The report maintains a "Buy" rating for the company, indicating a projected investment return exceeding 15% over the next 6-12 months [3]. Core Insights - The company is expected to achieve nearly 10% revenue growth in 2024, with a net loss not exceeding 275 million USD, representing a reduction of over 58% compared to the previous year [1][2]. - The overseas business revenue is projected to grow approximately 80% year-on-year, benefiting from the synergies and advantages of a global platform [1]. - The company has focused on core business areas, leading to stable revenue growth and a significant reduction in losses through various measures [2]. - The company is a leading player in high-value consumables, with strong R&D investment and a robust pipeline of products, including 36 green channel products and multiple regulatory approvals [3]. Financial Performance Summary - Revenue is expected to grow from 951 million USD in 2023 to 1,045 million USD in 2024, with a growth rate of 10% [5]. - The net loss is projected to decrease from 478 million USD in 2023 to 270 million USD in 2024, and further to 59 million USD in 2025, with a forecasted profit of 91 million USD in 2026 [5][9]. - The company has achieved a significant increase in revenue from its various business lines, including a 145%-155% increase in revenue from surgical robots and over 100% growth in overseas revenue from heart valve business [2][3].
微创医疗：2024年报业绩预告点评：聚焦业务，亏损如期大幅收窄-20250314